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Methicillin-resistant Staphylococcus aureus (MRSA)
with reduced vancomycin susceptibility vancomycin-inter-
mediate S. aureus (VISA) has been reported from many
countries. Whether resistance is evolving regularly in differ-
ent genetic backgrounds or in a single clone with a genetic
predisposition, as early results suggest, is unclear. We
have studied 101 MRSA with reduced vancomycin suscep-
tibility from nine countries by multilocus sequence typing
(MLST), characterization of SCCmec (staphylococcal chro-
mosomal cassette mec), and agr (accessory gene regula-
tor). We found nine genotypes by MLST, with isolates within
all five major hospital MRSA lineages. Most isolates
(88/101) belonged to two of the earliest MRSA clones that
have global prevalence. Our results show that reduced sus-
ceptibility to vancomycin has emerged in many successful
epidemic lineages with no clear clonal disposition.
Increasing antimicrobial resistance in genetically distinct
pandemic clones may lead to MRSA infections that will
become increasingly difficult to treat.
Methicillin-resistant Staphylococcus aureus (MRSA)is a major problem around the world, causing hospi-
tal-acquired infections and, more recently, infections in the
community (1,2). The glycopeptides, particularly van-
comycin, have been the mainstays of therapy for MRSA,
and the emergence of resistance to these agents is of great
concern.
The first S. aureus with reduced vancomycin suscepti-
bility (vancomycin MIC >8 µg/mL) was isolated in 1997
(3,4), and similar isolates have since been discovered in
several countries. These vancomycin-intermediate S.
aureus (VISA) isolates are relatively rare; a recent review
found 21 VISA described in the literature (5). However,
strains of S. aureus have been described that are van-
comycin-susceptible by conventional testing but have a
subpopulation of resistant cells. These heterogeneous
VISA (hVISA) are more common; reports from around the
world indicate that 0.5%–20% of MRSA are heteroresis-
tant (5). The clinical importance of hVISA is debatable,
but evidence shows that they are precursors of VISA, and
they have been implicated in treatment failure in deep-
seated infections (6,7).
A study of early VISA strains that used multilocus
sequence typing (MLST) and analysis of the SCCmec
region suggested that they were all descended from the
New York/Japanese (8,9) pandemic MRSA clone (10); the
first high-level vancomycin-resistant isolates that have
acquired the vanA gene cassette from enterococci are also
members of this clone (F. Tenover, pers. comm.).
Researchers have suggested that isolates of the New
York/Japanese pandemic MRSA clone may be predisposed
to become vancomycin resistant, perhaps because of loss-
of-function mutations in the agr (accessory gene regulator)
gene (11). We analyzed the genetic backgrounds of a geo-
graphically diverse sample of VISA and hVISA to investi-
gate the evolutionary history of such strains.
Materials and Methods
We collected 101 isolates of MRSA with reported het-
erogeneous or homogeneous resistance to vancomycin
(MIC > 8 mg/L) from China (n = 1), France (31), Japan
(2), Norway (14), Poland (13), Sweden (1), United
Kingdom (28), and the United States (11). Antimicrobial
susceptibility tests were performed by the agar dilution
method of the National Committee for Clinical Laboratory
Standards. Isolates were described as VISA if they fulfilled
the three criteria adopted by the Centers for Disease
Control and Prevention, that is, broth microdilution van-
comycin MIC of 8 to 16 mg/L, MIC > 6 mg/L on E-test,
and growth on brain-heart infusion agar containing 6 mg/L
vancomycin (12). Isolates with heterogeneous resistance to
vancomycin were confirmed by using population analysis
profiling followed by measuring the area under the curve
(PAP-AUC), as described previously (13). The prototypic
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hVISA strain MU3 was used as a standard, and isolates
with an AUC >0.9 compared to MU3 were described as
hVISA. 
MLST was performed as described previously (10). The
seven housekeeping gene sequences were compared to
known alleles in the MLST database (available from
http://www.mlst.net), and the resulting allelic profiles
(which define sequence types, STs) were used to interrogate
the databases for matches within records of the 988 isolates
held there. The MLST databases contain molecular and epi-
demiologic data on S. aureus isolates from carriage and dis-
ease, including examples of all major MRSA clones (10).
Data from this study were added to the S. aureus MLST
database, and the entire dataset was analyzed by using the
BURST algorithm to assign isolates to clonal complexes
(CCs), which are lineages containing genetically related
isolates (sharing 100% genetic identity at >5/7 loci used).
Polymerase chain reaction (PCR) analysis of the ccr (chro-
mosomal cassette recombinase) and mec (methicillin resist-
ance) regions was performed to discriminate the four main
SCCmec types (I–IV) on the basis of combinations of the
two regions. Conventional PCR was used to detect
SCCmec I–III by using the primers described in Ito et al.
(14) and SCCmec IV by using those described by Daum et
al. (15). These results were confirmed using the multiplex
method of Oliveira et al. (16). Detection of agr subgroups
I–IV was performed by PCR of the region surrounding
agrD, which codes for an autoinducing peptide, according
to the method of Peacock et al. (17).
Results and Discussion
The results are shown in the Table. PAP-AUC values
for the isolates varied from 0.9 to 3.01 and 91/101 isolates
were designated hVISA on the basis of a PAP-AUC value
>0.9. Nine isolates were designated as VISA. 
From the genotyping results, strains were divided into
clonal complexes, which can be subdivided according to
sequence type (ST) and SCCmec differences. The clonal
complexes CC5, CC8, CC22, CC30, and CC45 represent
the five pandemic MRSA lineages that have been previ-
ously described (10). Our results show that hVISA has
arisen in all five of these pandemic clones and that VISA
has so far developed in CC5 and CC8. The three most
common MRSA clones present in the United Kingdom
(EMRSA-3, EMRSA-15, EMRSA-16) (18) are included
within these lineages, and reduced vancomycin suscepti-
bility has been identified in all of these clones. All lineag-
es displayed resistance to multiple antimicrobial classes,
and only the new oxazolidinone linezolid was active
against all strains.
Only agr subgroups (alleles) I and II were found in iso-
lates in this study with 7/9 VISA and 57/92 hVISA having
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Table. Characteristics of study isolates with reduced vancomycin susceptibilitya 
Genotype Antimicrobial susceptibility*† 
CC ST SCCmec Clonal type agr type 
Vancomycin 
resistance 
phenotype 
(no. of strains) 
PAP-
AUC Country of origin Lzd Syn Gen Cip Rif 
II hVISA (1) 0.98 UK S S R R R 5 5 I EMRSA-3 
I VISA (1) 1.9 USA S S R R S 
II hVISA (10) 0.97–1.23 Japan, Sweden, France, 
Poland, UK, USA, 
Norway 
S S S/R S/R S/R 5 5 II New 
York/Japanese 
I or II VISA (3) 1.4–1.92 USA S S S R S/R 
5 5 IV Pediatric I or II hVISA (3) 1.19–1.32 UK S S S S/R S/R 
5 5 NT  I VISA (1) 1.44 France S S R R R 
8 8 I  II hVISA (3) 0.92–1.32 France, UK, Norway S S R R R 
8 8 II Irish-1 II hVISA (3) 1.04–1.2 France, USA, Norway S S S/R R S/R 
8 8 IV EMRSA-4, -6 I hVISA(11) 0.94–1.24 France, USA S S/R S/R R S/R 
22 22 IV EMRSA-15 I or II hVISA (7) 0.9–1.25 UK S S S R S/R 
25 25 NT  I hVISA(1) 1.13 UK S S R R R 
30 36 II EMRSA-16 II hVISA (3) 0.92–1.17 UK S S R R R 
45 45 II  I hVISA (1) 1 USA S S R R S 
I or II hVISA (10) 0.9–1.22 France, Poland, China, 
Norway, UK 
S S R S/R S/R 8 239 I or II Brazilian/ 
Portuguese 
I VISA (3) 1.44–3.01 France, Poland, UK S S/R R R S/R 
8 239 NT  I hVISA (1) 0.92 France S S R R R 
8 246 NT  I hVISA (1) 1.13 Norway S S R R R 
I VISA (1) 1.57 UK S S R R R 8 247 I Iberian 
I or II hVISA (37) 0.9–1.33 France, Poland, UK, 
Norway 
S S R R S/R 
aS, susceptible; R, resistant; NT, nontypeable; PAP-AUC, population analysis profiling followed by measuring the area under the curve; Lzd, linezolid; Syn, synercid; 
Gen, gentamicin; Cip, ciprofloxacin; Rif, rifampin; CC, clonal complex; ST, sequence type; EMRSA, methicillin-resistant Staphylococcus aureas found in the United 
Kingdom (UK) ; hVISA, heterogeneous vancomycin-intermediate S. aureus; USA, United States of America. 
agr I. Within the 14 clones in this study, the proportion of
isolates with particular agr alleles was variable. The pres-
ence of both agr I and agr II among VISA/hVISA, even in
genetically similar isolates, suggests that the genes for the
agr system are horizontally transferred. Sakoulas et al.
reported an association of agr II with the development of
vancomycin resistance (11). Our results show that
VISA/hVISA also emerged in strains with agr I.
Molecular analyses of VISA isolates to date have
focused on isolates from the United States and Japan, and
results have indicated that all strains belong to the New
York/Japanese MRSA clone. In our study, we found that
hVISA isolates have emerged from every lineage that has
produced pandemic MRSA clones, and VISA isolates have
emerged in two of five lineages, in all likelihood from
hVISA precursor isolates. 
Increasing drug resistance in clones that are multidrug
resistant and adapted to spread and cause serious disease
can do much damage in the modern hospital environment.
We have shown that reduced vancomycin susceptibility
has emerged in genetically and phenotypically diverse
MRSA clones throughout the world. This finding suggests
that vancomycin resistance has the potential to become a
widespread problem in MRSA strains already resistant to
multiple antimicrobial agents.
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